123
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey

ORCID Icon, , , ORCID Icon, , , ORCID Icon, ORCID Icon, , ORCID Icon, , & show all
Pages 1577-1587 | Published online: 12 Jul 2022

References

  • Soriano JB, Alfageme I, Miravitlles M, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol. 2021;57(1):61–69. doi:10.1016/j.arbres.2020.07.024
  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease (GOLD); 2021.
  • Miravitlles M, Calle M, Soler-Cataluña JJ. GesEPOC 2021: one more step towards personalized treatment of COPD. Arch Bronconeumol. 2021;57(1):9–10. doi:10.1016/j.arbres.2020.08.002
  • Miravitlles M, Calle M, Molina J, et al. Spanish COPD Guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69–81. doi:10.1016/j.arbres.2021.03.005
  • Monteagudo M, Nuñez A, Solntseva I, et al. Treatment pathways before and after triple therapy in COPD: a population-based study in primary care in Spain. Arch Bronconeumol. 2021;57(3):205–213. doi:10.1016/j.arbres.2020.07.032
  • Bloom CI, Douglas I, Usmani OS, Quint JK. Inhaled corticosteroid treatment regimens and health outcomes in a UK COPD population study. Int J Chron Obstruct Pulmon Dis. 2020;15:701–710. doi:10.2147/COPD.S241568
  • Stolz D, Miravitlles M. The right treatment for the right patient with COPD: lessons from the IMPACT trial. Eur Respir J. 2020;55(5):2000881. doi:10.1183/13993003.00881-2020
  • Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756. doi:10.1016/S2213-2600(19)30190-0
  • Miravitlles M, Monteagudo M, Solntseva I, Alcázar B. Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study. Arch Bronconeumol. 2021;57(1):13–20. doi:10.1016/j.arbres.2019.12.015
  • Izquierdo JL, Morena D, González Y, et al. Clinical management of COPD in a real-world setting. A big data analysis. Arch Bronconeumol. 2021;57(2):94–100. doi:10.1016/j.arbres.2019.12.025
  • Izquierdo Alonso JL, Rodríguez Glez-Moro JM. The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. Arch Bronconeumol. 2012;48(6):207–212. doi:10.1016/j.arbres.2012.01.002
  • Calle Rubio M, Rodríguez Hermosa JL, Soler-Cataluña JJ, et al. Medical care according to risk level and adaptation to Spanish COPD guidelines (Gesepoc): the Epoconsul Study. Arch Bronconeumol. 2018;54(5):270–279. doi:10.1016/j.arbres.2017.11.015
  • Casas A, Montes de Oca M, Menezes AM, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556. doi:10.2147/COPD.S154097
  • Izquierdo Alonso JL, Rodríguez González-Moro JM, de Lucas Ramos P, Martín Centeno A, Gobartt Vázquez E. ¿Ha cambiado el manejo de la EPOC en España? Resultados de un estudio multicéntrico comunitario (VICE). [Has the treatment of COPD changed in Spain? Results of a community multicenter study (VICE)]. Rev Clin Esp. 2008;208(1):18–25. Spanish. doi:10.1157/13115003
  • Barrecheguren M, Monteagudo M, Ferrer J, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med. 2016;111(111):47–53. doi:10.1016/j.rmed.2015.12.004
  • Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908. doi:10.2147/COPD.S139470
  • Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66(8):699–708. doi:10.1136/thx.2011.160028
  • Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(7). doi:10.1002/14651858.CD002991.pub3
  • Miravitlles M, Auladell-Rispau A, Monteagudo M, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160):210075. doi:10.1183/16000617.0075-2021
  • Tsiligianni I, Kampouraki M, Ierodiakonou D, Poulonirakis I, Papadokostakis P. COPD patients’ characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study. Int J Chron Obstruct Pulmon Dis. 2019;14:547–556. doi:10.2147/COPD.S185362
  • Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S62750
  • Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC
  • Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa1407154
  • Rossi A, van der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556. doi:10.1183/09031936.00126814
  • Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020;55:2000351. doi:10.1183/13993003.00351-2020
  • Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
  • Magnussen H, Lucas S, Lapperre T, et al. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respir Res. 2021;22(1):25. doi:10.1186/s12931-021-01615-0
  • Miravitlles M, Cosio BG, Arnedillo A, et al. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respir Res. 2017;18(1):198. doi:10.1186/s12931-017-0682-y
  • Golpe R, Dacal D, Sanjuán-López P, Martín-Robles I, Pérez-de-llano LA. Plasma eosinophil count and patient-centered events in chronic obstructive pulmonary disease in real-life clinical practice. Arch Bronconeumol. 2020;56(2):129–130.
  • Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest. 2015;148(5):1177–1183. doi:10.1378/chest.15-0627